E-Mail
IMAGE: Wistar scientists characterized an inhibitor that targets acetate metabolism in cancer cells. This molecule caused tumor growth inhibition and regression in preclinical studies, demonstrating the promise of this approach as. view more
Credit: The Wistar Institute
PHILADELPHIA (Jan. 7, 2021) Scientists at The Wistar Institute characterized an inhibitor that targets acetate metabolism in cancer cells. Cancer cells use acetate metabolism to support tumor growth in conditions of low nutrient and oxygen availability. This molecule caused tumor growth inhibition and regression in preclinical studies, demonstrating the promise of this approach as a novel therapeutic strategy for solid tumors. Study results were published today in
New Group of Antibiotics Active Against Various Bacteria by Angela Mohan on December 24, 2020 at 11:00 AM
Nature, by Wistar Institute scientists. We took a creative, double-pronged strategy to develop new molecules that can kill difficult-to-treat infections while enhancing the natural host immune response, said Farokh Dotiwala, M.B.B.S., Ph.D., assistant professor in the Vaccine & Immunotherapy Center and lead author of the effort to identify a new generation of antimicrobials named dual-acting immuno-antibiotics (DAIAs).
Current antibiotics target nucleic acid and protein synthesis, building of the cell membrane, and metabolic pathways. But, bacteria can acquire drug resistance by modifying the bacterial target or by inactivating the drugs or pumping them out.
Scientists Develop Novel Class of Antibiotic against Wide Range of Bacteria
Source: The Wistar Institute
December 23, 2020
Wistar Institute scientists have designed a new class of antimicrobial compound, which, they claim, uniquely combines direct antibiotic killing of pan drug-resistant pathogenic bacteria, with a simultaneous rapid immune response for combating antimicrobial resistance (AMR). The team claims the dual-acting immuno-antibiotics (DAIA) strategy could represent a “landmark” in the fight against AMR.
“We took a creative, double-pronged strategy to develop new molecules that can kill difficult-to-treat infections while enhancing the natural host immune response,” said Farokh Dotiwala, MBBS, PhD, assistant professor in the Vaccine & Immunotherapy Center and lead author of the team’s work, which is reported in
Credit: The Wistar Institute
PHILADELPHIA (Dec. 23, 2020) Wistar Institute scientists have discovered a new class of compounds that uniquely combine direct antibiotic killing of pan drug-resistant bacterial pathogens with a simultaneous rapid immune response for combatting antimicrobial resistance (AMR). These finding were published today in
Nature.
The World Health Organization (WHO) has declared AMR as one of the top 10 global public health threats against humanity. It is estimated that by 2050, antibiotic-resistant infections could claim 10 million lives each year and impose a cumulative $100 trillion burden on the global economy. The list of bacteria that are becoming resistant to treatment with all available antibiotic options is growing and few new drugs are in the pipeline, creating a pressing need for new classes of antibiotics to prevent public health crises.